Cargando…

Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)

Aim: The morbidity of cardiovascular disease in patients with type 2 diabetes mellitus (DM) deteriorates in combination with dyslipidemia. The accumulation of remnant lipoproteins in patients with fasting and postprandial hypertriglyceridemia is highly atherogenic. The current study investigated whe...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Daisaku, Kobayashi, Takuya, Sairyou, Masami, Hanada, Hiroyuki, Ohama, Tohru, Koseki, Masahiro, Nishida, Makoto, Maeda, Norikazu, Kihara, Shinji, Minami, Tatsuya, Yanagi, Koji, Sakata, Yasushi, Yamashita, Shizuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005231/
https://www.ncbi.nlm.nih.gov/pubmed/29199201
http://dx.doi.org/10.5551/jat.41343
_version_ 1783332657706303488
author Masuda, Daisaku
Kobayashi, Takuya
Sairyou, Masami
Hanada, Hiroyuki
Ohama, Tohru
Koseki, Masahiro
Nishida, Makoto
Maeda, Norikazu
Kihara, Shinji
Minami, Tatsuya
Yanagi, Koji
Sakata, Yasushi
Yamashita, Shizuya
author_facet Masuda, Daisaku
Kobayashi, Takuya
Sairyou, Masami
Hanada, Hiroyuki
Ohama, Tohru
Koseki, Masahiro
Nishida, Makoto
Maeda, Norikazu
Kihara, Shinji
Minami, Tatsuya
Yanagi, Koji
Sakata, Yasushi
Yamashita, Shizuya
author_sort Masuda, Daisaku
collection PubMed
description Aim: The morbidity of cardiovascular disease in patients with type 2 diabetes mellitus (DM) deteriorates in combination with dyslipidemia. The accumulation of remnant lipoproteins in patients with fasting and postprandial hypertriglyceridemia is highly atherogenic. The current study investigated whether the dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates dyslipidemia and hyperglycemia. Methods: We enrolled 38 patients with type 2 DM (20 males and 18 females, 65.7 ± 9.9 years old, HbA1c levels < 8.4%), and all patients gave written informed consent. Sitagliptin (50 mg/day) was added to current antidiabetic treatments and increased to 100 mg/day to achieve low HbA1c levels (< 7.4%). Glucose and lipoprotein metabolism profiles were analyzed at 0, 4, and 12 weeks after sitagliptin administration. Results: Sitagliptin significantly decreased fasting levels of triglyceride (TG) (161 ± 90 vs. 130 ± 66 mg/dl, p < 0.01) and non-HDL-C (129 ± 29 vs. 116 ± 20 mg/dl, p < 0.01) in combination with glucose (150 ± 47 vs. 129 ± 27 mg/dl, p < 0.01) and HbA1c (7.1 ± 0.6 vs. 6.6 ± 0.7 mg/dl, p < 0.001). Sitagliptin also significantly decreased the fasting levels of apolipoprotein (apo) B-48 (7.8 ± 6.7 vs. 5.6 ± 4.0 µg/ml, p < 0.01), remnant lipoprotein cholesterol (15.3 ± 9.5 vs. 12.0 ± 7.9 mg/dl, p < 0.05) and other apolipoproteins, such as apoB, apoC-II, apoC-III, and apoE. Analyses of the lipoprotein profiles of fasting sera revealed that sitagliptin significantly decreased cholesterol and TG levels of lipoprotein fractions in the size of very low density lipoprotein and low density lipoprotein. Conclusions: These findings indicated that sitagliptin administration ameliorated the lipid and lipoprotein profiles in patients with diabetes, which may be due to the decrease in atherogenic remnant lipoproteins (UMIN#000013218). Abbreviations: apo: apolipoprotein ASCVD: atherosclerotic cardiovascular disease CHD: coronary heart disease CLEIA: chemiluminescence enzyme immunoassay CM: Chylomicron DPP-4: dipeptidyl peptidase-4 FFAs: free fatty acids HPLC: high-performance liquid chromatography IMT: intima-media thickness LDL: low-density lipoprotein LPL: lipoprotein lipase PHTG: postprandial hypertriglyceridemia RemL-C: remnant lipoprotein cholesterol RLP-C: remnant-like particle cholesterol TG: triglyceride TRL: triglyceride-rich lipoprotein VLDL: very low density lipoprotein
format Online
Article
Text
id pubmed-6005231
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Japan Atherosclerosis Society
record_format MEDLINE/PubMed
spelling pubmed-60052312018-06-19 Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial) Masuda, Daisaku Kobayashi, Takuya Sairyou, Masami Hanada, Hiroyuki Ohama, Tohru Koseki, Masahiro Nishida, Makoto Maeda, Norikazu Kihara, Shinji Minami, Tatsuya Yanagi, Koji Sakata, Yasushi Yamashita, Shizuya J Atheroscler Thromb Original Article Aim: The morbidity of cardiovascular disease in patients with type 2 diabetes mellitus (DM) deteriorates in combination with dyslipidemia. The accumulation of remnant lipoproteins in patients with fasting and postprandial hypertriglyceridemia is highly atherogenic. The current study investigated whether the dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates dyslipidemia and hyperglycemia. Methods: We enrolled 38 patients with type 2 DM (20 males and 18 females, 65.7 ± 9.9 years old, HbA1c levels < 8.4%), and all patients gave written informed consent. Sitagliptin (50 mg/day) was added to current antidiabetic treatments and increased to 100 mg/day to achieve low HbA1c levels (< 7.4%). Glucose and lipoprotein metabolism profiles were analyzed at 0, 4, and 12 weeks after sitagliptin administration. Results: Sitagliptin significantly decreased fasting levels of triglyceride (TG) (161 ± 90 vs. 130 ± 66 mg/dl, p < 0.01) and non-HDL-C (129 ± 29 vs. 116 ± 20 mg/dl, p < 0.01) in combination with glucose (150 ± 47 vs. 129 ± 27 mg/dl, p < 0.01) and HbA1c (7.1 ± 0.6 vs. 6.6 ± 0.7 mg/dl, p < 0.001). Sitagliptin also significantly decreased the fasting levels of apolipoprotein (apo) B-48 (7.8 ± 6.7 vs. 5.6 ± 4.0 µg/ml, p < 0.01), remnant lipoprotein cholesterol (15.3 ± 9.5 vs. 12.0 ± 7.9 mg/dl, p < 0.05) and other apolipoproteins, such as apoB, apoC-II, apoC-III, and apoE. Analyses of the lipoprotein profiles of fasting sera revealed that sitagliptin significantly decreased cholesterol and TG levels of lipoprotein fractions in the size of very low density lipoprotein and low density lipoprotein. Conclusions: These findings indicated that sitagliptin administration ameliorated the lipid and lipoprotein profiles in patients with diabetes, which may be due to the decrease in atherogenic remnant lipoproteins (UMIN#000013218). Abbreviations: apo: apolipoprotein ASCVD: atherosclerotic cardiovascular disease CHD: coronary heart disease CLEIA: chemiluminescence enzyme immunoassay CM: Chylomicron DPP-4: dipeptidyl peptidase-4 FFAs: free fatty acids HPLC: high-performance liquid chromatography IMT: intima-media thickness LDL: low-density lipoprotein LPL: lipoprotein lipase PHTG: postprandial hypertriglyceridemia RemL-C: remnant lipoprotein cholesterol RLP-C: remnant-like particle cholesterol TG: triglyceride TRL: triglyceride-rich lipoprotein VLDL: very low density lipoprotein Japan Atherosclerosis Society 2018-06-01 /pmc/articles/PMC6005231/ /pubmed/29199201 http://dx.doi.org/10.5551/jat.41343 Text en 2018 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Original Article
Masuda, Daisaku
Kobayashi, Takuya
Sairyou, Masami
Hanada, Hiroyuki
Ohama, Tohru
Koseki, Masahiro
Nishida, Makoto
Maeda, Norikazu
Kihara, Shinji
Minami, Tatsuya
Yanagi, Koji
Sakata, Yasushi
Yamashita, Shizuya
Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)
title Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)
title_full Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)
title_fullStr Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)
title_full_unstemmed Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)
title_short Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)
title_sort effects of a dipeptidyl peptidase 4 inhibitor sitagliptin on glycemic control and lipoprotein metabolism in patients with type 2 diabetes mellitus (gloria trial)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005231/
https://www.ncbi.nlm.nih.gov/pubmed/29199201
http://dx.doi.org/10.5551/jat.41343
work_keys_str_mv AT masudadaisaku effectsofadipeptidylpeptidase4inhibitorsitagliptinonglycemiccontrolandlipoproteinmetabolisminpatientswithtype2diabetesmellitusgloriatrial
AT kobayashitakuya effectsofadipeptidylpeptidase4inhibitorsitagliptinonglycemiccontrolandlipoproteinmetabolisminpatientswithtype2diabetesmellitusgloriatrial
AT sairyoumasami effectsofadipeptidylpeptidase4inhibitorsitagliptinonglycemiccontrolandlipoproteinmetabolisminpatientswithtype2diabetesmellitusgloriatrial
AT hanadahiroyuki effectsofadipeptidylpeptidase4inhibitorsitagliptinonglycemiccontrolandlipoproteinmetabolisminpatientswithtype2diabetesmellitusgloriatrial
AT ohamatohru effectsofadipeptidylpeptidase4inhibitorsitagliptinonglycemiccontrolandlipoproteinmetabolisminpatientswithtype2diabetesmellitusgloriatrial
AT kosekimasahiro effectsofadipeptidylpeptidase4inhibitorsitagliptinonglycemiccontrolandlipoproteinmetabolisminpatientswithtype2diabetesmellitusgloriatrial
AT nishidamakoto effectsofadipeptidylpeptidase4inhibitorsitagliptinonglycemiccontrolandlipoproteinmetabolisminpatientswithtype2diabetesmellitusgloriatrial
AT maedanorikazu effectsofadipeptidylpeptidase4inhibitorsitagliptinonglycemiccontrolandlipoproteinmetabolisminpatientswithtype2diabetesmellitusgloriatrial
AT kiharashinji effectsofadipeptidylpeptidase4inhibitorsitagliptinonglycemiccontrolandlipoproteinmetabolisminpatientswithtype2diabetesmellitusgloriatrial
AT minamitatsuya effectsofadipeptidylpeptidase4inhibitorsitagliptinonglycemiccontrolandlipoproteinmetabolisminpatientswithtype2diabetesmellitusgloriatrial
AT yanagikoji effectsofadipeptidylpeptidase4inhibitorsitagliptinonglycemiccontrolandlipoproteinmetabolisminpatientswithtype2diabetesmellitusgloriatrial
AT sakatayasushi effectsofadipeptidylpeptidase4inhibitorsitagliptinonglycemiccontrolandlipoproteinmetabolisminpatientswithtype2diabetesmellitusgloriatrial
AT yamashitashizuya effectsofadipeptidylpeptidase4inhibitorsitagliptinonglycemiccontrolandlipoproteinmetabolisminpatientswithtype2diabetesmellitusgloriatrial